Navigation Links
KemPharm Completes Successful End-of-Phase 2 Meeting with FDA

NORTH LIBERTY, Iowa, Nov. 1, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201 (benzhydrocodone hydrochloride and acetaminophen).  Based on the results of the meeting, KemPharm believes the completed and ongoing clinical, non-clinical and CMC development programs will allow for the submission of a New Drug Application (NDA) for KP201 in the third quarter of 2014.

During the meeting, representatives from the FDA reviewed KemPharm's current portfolio of data for KP201, including the recently completed bioequivalence and "steady-state" pivotal clinical studies.  It was determined that the final data package, as proposed by KemPharm, would support a potential 505(b)(2) filing pathway without any additional efficacy, toxicology or safety data being required.

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, "The positive feedback we received from the Agency re-affirms prior discussions related to our clinical and non-clinical program for KP201 and our plan to pursue an NDA via the 505(b)(2) pathway. Based on their advice, we are extremely confident in our plan to submit an NDA by the third quarter of 2014 and seek potential approval of the first novel pain therapy of the morphine class to be developed in a number of years with an officially recognized new chemical structure."

KP201 is in development for the treatment of acute moderate to moderately severe pain. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC).

Mickle continued, "The next clinical milestone for KP201 will be the completion of oral and intranasal abuse liability studies in the first quarter of 2014.  These studies will be important indicators of KP201's unique abuse-deterrent capabilities, which we believe are unlike any prescription opioid on the market or in development."

About KemPharm

KemPharm is abiopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the third quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, KP606, its oxycodone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at

For KemPharm, Inc:   

Media / Investor Contacts:

Christal Mickle


Jason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.


SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
2. KemPharms KP201 Featured at the International Conference on Opioids
3. Micropharma completes development of first microbiome clinical lab test using digital PCR technology
4. Syneron Medical Completes and Summarizes the Multi-site Clinical Study Agreed Upon with FDA for the UltraShape Contour I
5. AIS (American Internet Services) Completes Audit for Title 21 CFR Part 11 Compliance
6. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
7. VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
8. Boston Scientific Completes $1.05 Billion Senior Notes Offering
9. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
10. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
11. Oligomerix, Inc. Completes Series B Financing
Post Your Comments:
(Date:12/1/2015)... Dec. 01, 2015 ... of the "2016 Europe Cell Surface ... Technologies, Competitive Strategies, Opportunities for Suppliers--France, Germany, ... offering. --> ) has ... Europe Cell Surface Markers: Country Volume and ...
(Date:12/1/2015)... -- Symic, a clinical-stage biotherapeutics company developing multiple compounds that ... that it has secured $25 million in a Series ... lead candidates SB-030 and SB-061. The financing was led ... existing major investors, as well as several new investors. ... Symic to over $43 million since being founded in ...
(Date:12/1/2015)... 1, 2015 ... "2016 U.K. Virology and Bacteriology Testing Market: ... Tests, Supplier Shares by Test, Innovative Technologies, ... offering.  --> ) has ... Virology and Bacteriology Testing Market: Sales and ...
(Date:11/30/2015)... radiology technique shows promise for helping morbidly obese patients lose ... presented today at the annual meeting of the Radiological Society ... --> --> Gastric artery embolization ... way to stop bleeding in emergency situations, but the idea ... is new. Mubin Syed , M.D., interventional radiologist ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015 Paris from 17 ... Paris from 17 th until 19 ... innovation leader, has invented the first combined scanner in the ... same scanning surface. Until now two different scanners were required: one ... capture both on the same surface. This innovation is ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , an ... of clinical research, is pleased to announce that it will ... Trials (PCT) event, to be held November 17-19 in ... to view live demonstrations of iMedNet , ... how iMedNet has been able to deliver time ...
Breaking Biology News(10 mins):